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Abstract
Objective: In this study the effect of ribose on heart
function and infarct-size was analyzed 6 h after
myocardial infarction (MI) in rats. Methods:
Continuous i.v.-infusion of NaCl or ribose (200 mg/
kg/h) was started one day prior to induction of MI in
female Sprague-Dawley rats which was done by
ligation of the left coronary artery. Six hours after MI
heart function was measured with 3F tip catheter,
cardiac output by thermodilution method. Thereafter
the ischemic area was delineated by Evans Blue
infusion, and the infarct area was visualized by
triphenyltetrazolium chloride staining. The mRNA
expression of interleukin (IL)-1β, IL-6, matrix-
metalloproteinase (MMP)-8, and -9 was measured by
ribonuclease protection assay. Results: Heart function
was severely depressed 6 hours after coronary artery
occlusion, but recovered significantly under the
influence of ribose. Left ventricular (LV) systolic
pressure (LVSP) and contractility (LVdP/dtmax) were
restored to the normal levels of sham-operated
animals, while parameters of LV relaxation (LVdP/dtmin
and time constant of relaxation τ) were impaired
compared to sham-operated animals, but significantly
improved by ribose treatment compared to sham-
treated MI-rats. Moreover, the infarct size was
significantly smaller in the ribose treated animals
despite a comparable ischemic area at risk in all
MI-rats. The cytokine mRNA expression after MI was
significantly reduced after ribose treatment, while
there were no differences regarding MMP expression.
Conclusion: MI size was significantly reduced and LV
function significantly improved by ribose treatment at
6 h after MI. This seemed to be based on slowing the
velocity of the necrotic wave front across the LV wall
after MI resulting in smaller infarcts.
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Introduction
Myocardial ischemia and infarction result in severe
reduction of overall cardiac pump function due to loss of
contractile mass [1]. This leads to numerous molecular,
structural, and metabolic alterations. These include
changes in the expression of components of the
extracellular matrix like collagens, colligin, and matrix-
metalloproteinases (MMPs) as well as of cytokines like
interleukins and TGF-β isoforms [2, 3]. The metabolic
alterations include a reduction in ATP content and
mitochondrial ATP synthase, glycogen depletion,
formation of lactic acid, accumulation of fatty acids,
inhibition of β-oxidation, and depression of mitochondrial
function [4-6]. The imbalance between the rate of
oxidative phosphorylation and the utilization of high energy
phosphates results in a progressive decrease of ATP levels
in the myocardium [7]. The degradation products finally
diffuse out of the myocytes with myocardial perfusion
[4]. This is deleterious, because high energy phosphates
are essential for myocardial contraction, relaxation and
maintenance of cellular integrity [8]. Alterations of
myocardial energy phosphate levels, accumulation of
extracellular Ca2+ and reactive oxygen species further
contribute to cell death by necrosis and apoptosis [9].
Even when ischemia ends and although fuels for
generation of ATP by oxidative phosphorylation like
glycogen and fatty acids are usually available, restoration
of ATP levels takes several days and is costly, since it
depends on de novo synthesis, due to the loss of ATP
precursors from the myocytes [4, 10].
ATP is synthesized from blood supplied glucose that
can be converted to 5-Phosphoribosyl-1-pyrophosphate
(PRPP) through the pentose phosphate pathway (PPP).
The relevance of this pathway has recently been
demonstrated by increased myocardial dysfunction after
ischemia/reperfusion in mice lacking Glucose-6-Phosphate
Dehydrogenase [11]. The activity of Glucose-6-Phosphate
Dehydrogenase and Phosphogluconat Dehydrogenase
limit the rate of the PRPP production. The pentose sugar
ribose bypasses the rate-limiting steps of the PRPP
synthesis and stimulates the salvage as well as the de
novo synthesis of nucleotides by increasing PRPP [12].
In cardiac myocytes, ribose increases ATP and decreases
NAD content without influences on the adenosine content
[13]. Furthermore, ribose has no influence on coronary
blood flow, myocardial oxygen consumption, and
hemodynamics in the normal heart. Therefore, ribose has
been suggested to be an attractive nutraceutical
supplement for the metabolic support of the heart in
numerous cardiac disorders [14-18].
Previous studies have shown that ribose
administration increases the PRPP pool [16, 19] and
improves ventricular function in different
pathophysiological states that are accompanied by ATP
reduction [20, 21]. In experimental in vivo models in rats
such as in the overloaded or the catecholamine-stimulated
heart, the normalization of the metabolic situation by ribose
administration was accompanied by an improvement of
global heart function [20]. Also after temporary local
ischemia, ribose accelerated the replenishment of the
adenine nucleotide pool and improved the return of
function [22]. Furthermore, ribose pretreatment
significantly elevated the heart’s energy stores (glycogen),
and delayed the onset of irreversible ischemic injury [23].
In spontaneously hypertensive rats, however, ribose had
no effect on ischemic tolerance, but improved left
ventricular function [23]. Additionally, application of ribose
in combination with adenine and verapamil decreased
Ca2+ level and increased level of high energy phosphates
after global ischemia in isolated rat hearts [24].
Therefore, we hypothesized that treatment before
and during ischemia with ribose might reduce the ischemic
injury and also prevent LV dysfunction in an acute stage
of MI. Accordingly, the objective of the study was to
evaluate the effects of i.v. infusion of ribose 24 h prior to
permanent coronary artery ligation on infarct size,
ventricular function, and expression of cytokines in rats.
Materials and Methods
Animal model
A total of 73 female Sprague-Dawley rats (3.5 months of
age and 251±6 g of body weight) were used in this study. The
investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996) and was
approved by the appropriate Federal State Agency. The rats
were anesthetized with 2 % isoflurane and randomized to receive
either intravenous infusion (i.v.) of 0.9% sodium chloride (NaCl)
or D-Ribose (200 mg/kg/h). All substances were administered
as continuous i.v. infusion via a catheter (Vygon) placed in the
left jugular vein. Each catheter was connected to a 50 ml syringe
placed in an infusion pump (Infors) and the infusion rate was
set to 4 ml/kg/h as previously described [20]. After implantation
of the infusion catheter, the animals were allowed to recover
from anesthesia in individuals cages with free access to water
and rat chow.
After 24 hours of i.v. infusion, myocardial infarction was
induced by ligation of the left anterior descending coronary
artery (LAD) under ether anesthesia as previously described
[3, 25]. Briefly, the fourth intercostal space was opened, the
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heart was exteriorized, and the pericardium was cut. The LAD
was ligated between the left auricle and the pulmonary outflow
tract with a monofil thread (Ethicon USP 6/0, Johnson+Johnson)
while holding the apex of the heart with forceps. Thereafter, the
chest was closed and the rats were allowed to recover. Due to
the mortality after acute MI (overall 29%), not all animals
completed the study (n=10 for MI+NaCl and n=18 for MI+R).
In an additional group, MI was induced in rats without any
treatment (MI-CTRL, n=11). Sham-operated animals underwent
the same procedure except that no ligation was performed
(sham, total n=18, each n=6 for sham-CTRL, sham+NaCl and
sham+R, respectively).
Hemodynamic measurements
Heart function was measured 6 h after surgery in closed-
chest spontaneously breathing rats anesthetized with
thiopental sodium (Trapanal® 60 mg/kg i.p., Byk Gulden) using
ultraminiature catheter pressure-transducers (3 F, Millar
Instruments Inc.) as previously described [2, 3]. Briefly, the LV
catheter (model SPR-249) was placed in the right carotid artery
and advanced upstream to the aorta and into the LV. Heart rate
(HR), right and left ventricular (RV and LV, respectively) pressure
and the rate in rise and fall of ventricular pressure (LV and
RVdP/dt, respectively) were recorded continuously on a PC at
a sampling rate of 2 kHz using DASYLab V7.0 software (National
Instruments) for 10 - 15 min. During the hemodynamic
measurements, also the ECG was recorded via needle electrodes
to verify successful induction of MI. Cardiac output was
measured by the thermodilution method (Cardiomax IIR,
Columbus Instruments).
Tissue collection and infarct size measurement
After the hemodynamic measurements had been
obtained, Evans blue solution was infused to delineate the
ischemic area at risk (AAR). Thereafter, the hearts were
removed, cut into slices of about 2 mm and incubated in 1%
triphenyltetrazolium chloride (TTC) in 0.1 M phosphate buffer,
pH 7.4, at 37°C for 15 min. Then, stained slices were fixed with
10% formaldehyde overnight and scanned as previously
described [26]. The AAR and the infarct size were determined
via planimetry by using image analyzer software (Image Pro
Plus 4.5), and the infarct area was calculated as the percentage
of the AAR.
In additional experiments the hearts were rapidly excised
after the hemodynamic measurements. Myocardial infarction
was determined by the inspection of the pale zone on the LV
free wall. The RV free wall was trimmed away and the infarct
area was cut from the non-infarcted LV additionally leaving a
border zone of about 2 mm in width. The tissue pieces were
snap frozen in liquid nitrogen for RNA isolation.
RNase Protection Assay (RPA)
Total RNA was isolated using the Trizol®-Reagent
(GibcoBRL) according to the protocol supplied by the
manufacturer. For the RNase protection assay (RPA), 5µg or
7.5µg of total RNA were used for the expression analysis of
matrix metalloproteinases (MMP) or cytokines, respectively
[2, 3]. The cytokine probe template set rCK1 was obtained from
BD PharMingen while the MMP template set was generated
by RT-PCR as previously described [2]. Each probe template
set was labeled with [α-32P]-UTP (3000 Ci/mmol, Amersham) by
means of RiboQuant® In Vitro Transcription Kit (BD
PharMingen) as described by the manufacturer. After
hybridization (final concentration: 8x103 cpm/µl for each probe
in template set) at 56°C for 12-16 h the unhybridized riboprobe
was digested with a mixture of RNases A and T1 (RiboQuant®
RPA Kit, BD PharMingen) according to the manufacturer’s
instructions. Protected probes were electrophoresed on a
denaturing gel containing 5 % polyacrylamide/8 M urea and
visualized and quantified using the Molecular Imager®FX and
QuantityOne4.4 software (BioRad). The signals of specific
mRNAs were normalized to those of GAPDH mRNA.
Statistical analysis
The results were expressed as mean ± SEM. Statistical
significance was evaluated by one way ANOVA for multiple
samples subsequently utilizing multigroup comparison
procedure according to Newman-Keuls using SigmaStat2.0
(Jandel). A value of p<0.05 was considered statistically
significant, but the significance level was adjusted according
to the number of groups.
Results
Effects of ribose on Left Ventricular Function
Heart function was severely impaired 6 h after
coronary artery occlusion (Fig. 1). Left ventricular systolic
pressure (LVSP) as well as the maximal rates of rise
and fall in ventricular pressure (LVdP/dtmax and LVdP/
dtmin, respectively) were greatly reduced while left
ventricular end-diastolic pressure (LVEDP) and the time
constant of early relaxation τ were significantly increased.
This impairment in LV function was comparable between
sham-treated animals (MI+NaCl) and MI rats without
any infusion (MI-CTRL). Infusion of ribose (MI+R),
however, restored LVSP and LVdP/dtmax to the level of
sham-operated controls (Fig. 1). Also LVdP/dtmin and τ
improved after ribose treatment, but remained significantly
impaired compared to sham-operated controls. Enhanced
global pump function was also evident by significantly
increased cardiac output in the ribose treated rats relative
to sham-operated and sham-treated animals (Fig. 2). Total
peripheral resistance (TPR) increased after the infusion
of both, NaCl or ribose, but reached statistical significance
only in the ribose treated rats. The heart rate (HR) was
comparable between all groups (Fig. 2).
Effects of ribose on infarct size
The ischemic area at risk was comparable between
all MI-groups, but treatment with ribose significantly
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reduced the resulting infarct size as compared to untreated
or sham-treated MI rats (Fig. 3).
Effects of ribose on mRNA expression
At 6 h post MI, IL-6 and IL-1β significantly
increased in the infarct area of MI and MI+NaCl groups
as compared with sham-operated hearts. This increase
was significantly attenuated in the hearts of ribose treated
animals (Fig. 4). Also the expression of MMP-8 and 9
increased after MI as compared with sham-operated
controls (Fig. 5). This increase was significantly
pronounced in both groups of MI animals that received
an infusion of either NaCl or ribose (p<0.05 vs
MI-CTRL). There were, however, no differences in the
expression of MMP-8 and 9 between MI+NaCl and
MI+R (Fig. 5).
Discussion
The present study shows that i.v. infusion of ribose
from 24 h prior to and up to 6 h after permanent coronary
artery ligation in rats reduces the infarct size, prevents
systolic and diastolic ventricular dysfunction and the
increase of cytokine expression.
Myocardial infarction induced severe systolic and
diastolic dysfunction (Figs. 1 and 2) and increased the
expression of pro-inflammatory cytokines and MMPs
(Figs. 4 and 5). At 6 h after MI, LV dysfunction was
characterized by a decline of systolic pressure, contractility,
and cardiac output and by an increase in LVEDP and a
delayed relaxation rate. The main difference between
untreated (MI-CTRL) and sham-treated MI rats
(MI+NaCl) was the small increase in MMP expression
Fig. 1. Upper panels: Original recordings of hemodynamic measurements 6 h after MI+NaCl (left) of MI+R (right). Lower panels:
Quantitative summary of left ventricular (LV) systolic pressure (LVSP), end-diastolic pressure (LVEDP), and rates of rise and fall
of ventricular pressure (LVdP/dtmax and LVdP/dtmin, respectively) 6 h after sham operation (sham, n = 6 for each sham group),
untreated MI (MI-CTRL, n = 11), MI treated with NaCl (MI+NaCl, n = 10) or MI treated with ribose (MI+R, n = 18); # p < 0.05 vs
sham-CTRL; * p < 0.05 vs corresponding sham; † p < 0.05 vs MI-CTRL; ‡ p < 0.05 vs MI+NaCl.
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in the latter group probably induced by the considerable
volume of the infusion. The infusion of ribose significantly
reduced the infarct size and restored systolic pressure
and contractility essentially to the normal level of sham-
operated controls (Fig. 1). Furthermore, the relaxation
rate (LVdP/dtmin and τ; Figs. 1 and 2, respectively) was
improved and the reduction in cardiac output normalized
to body weight (COI, Fig. 2) was attenuated by ribose
treatment. The rather moderate increase in LVEDP after
6 h may indicate that bulging of the non-infarcted heart
did not occur at this time; only later, LVEDP elevations
have been regularly observed [2, 3, 20]. The volume of
the infusion is unlikely to contribute to changes in the
LVEDP, since there were no differences in LVEDP
between treated and untreated (MI-CTRL) rats and,
furthermore, the volume was the same for ribose and
NaCl. The improvement in the relaxation rate may follow
the favorable effect of ribose on contractility.
Interestingly, the reduction in infarct size and the
improvement in heart function by ribose after MI were
accompanied by attenuation of the IL-1β and IL-6
expression (Fig. 4). Although the role of both cytokines
after acute myocardial injury it is still not clear, it has
been shown that the myocytes in the ischemic area are a
major source of their expression [27]. Therefore, it may
be suggested that the attenuation of their expression after
Fig. 2. Quantitative summary of heart rate (HR), time constant of relaxation tau (τ), cardiac output index (COI)
and total peripheral resistance (TPR) 6 h after sham operation (sham), untreated MI (MI-CTRL), MI treated
with NaCl (MI+NaCl) or MI treated with ribose (MI+R); § p < 0.05 vs sham-CTRL and sham+NaCl; * p < 0.05 vs
corresponding sham; † p < 0.05 vs MI-CTRL; ‡ p < 0.05 vs MI+NaCl.
Fig. 3. Left: Planimetric
measurements of ischemic area
(area at risk) and the infarct area
(% of area at risk) 6 h after
untreated MI (MI-CTRL), NaCl
treated MI (MI+NaCl) or ribose
treated MI (MI+R); † p < 0.05 vs
MI-CTRL; ‡ p < 0.05 vs MI+NaCl.
Right: Representative photo-
graphs of Evans-Blue/TTC
stained heart sections 6 h after
MI-CTRL (upper), MI+NaCl
(middle) and MI+R (bottom).
Ribose Treatment for MI in Rats Cell Physiol Biochem 2009;24:211-218
216
MI by ribose may reflect a less severe ischemic injury.
However, it cannot be decided whether attenuation of
IL-1β and IL-6 expression contributes to the prevention
of infarct extension or whether it may just be a secondary
effect of infarct size reduction. Most MMPs, on the other
hand, are usually not expressed in normal tissue.
Particularly MMP-8 and -9 are mainly produced by
neutrophils or macrophages, respectively. This would
indicate that the post-ischemic infiltration of the
myocardium was not influenced by ribose treatment.
However, also an effect of the volume load has to be
considered (Fig. 5), but both aspects were not studied in
further detail.
Previous studies showed that myocytes have
alternative means of producing energy that would allow
reversing the imbalance between oxygen supply and
demand, as it occurs in a situation of ischemia [28]. It is,
however, a characteristic metabolic feature of the myocyte
to very slowly restore their adenine nucleotide pool after
it has been depleted [29]. It has been shown that myocytes
find two alternative pathways for ATP production under
these conditions that would allow them reversing the
ventricular dysfunction [14]. The first one would involve
adenosine, inosine, and adenine (salvage pathway); and
the second would be by stimulating adenine nucleotide
biosynthesis. The latter can be achieved by means of
ribose. This pentose sugar can permeate the cell
membrane and enhance the adenine nucleotide
biosynthesis by bypassing the rate-limiting enzymatic steps
in the PPP through conversion to ribose-5-phosphate and
formation of 5-phosphoribosyl-1-pyrophosphate [30]. That
this is a specific function of ribose has been shown in
that glucose did not have any of the ribose effects [17,
31]. The current study substantiates the hypothesis that
i.v. infusion of ribose from 24 h prior to permanent
coronary artery ligation and during permanent ischemia
protects the heart from irreversible injury after 6 h of
myocardial infarction.
The effect of ribose administration has been assessed
in several experimental models with depressed heart
Fig. 4. Left: Quantitative
summary of mRNA-Expres-
sion of interleukin (IL)-1β and
-6 6 h after sham operation
(sham), untreated MI (MI-
CTRL), MI treated with NaCl
(MI+NaCl) or MI treated
with ribose (MI+R); # p < 0.05
vs sham-CTRL; * p < 0.05 vs
corresponding sham;
† p < 0.05 vs MI-CTRL;
‡ p < 0.05 vs MI+NaCl. Right:
Representative ribonuclease
protection assay (RPA) of
mRNA-Expression of
IL-1β and -6.




and -9 6 h after sham
operation (sham), untreated
MI (MI-CTRL), MI treated
with NaCl (MI+NaCl) or MI
treated with ribose (MI+R);
# p < 0.05 vs sham-CTRL;
* p < 0.05 vs corresponding
sham; † p < 0.05 vs MI-CTRL.
Right: Representative
ribonuclease protection
assay (RPA) of mRNA-
Expression of MMP -8 and -9.
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function associated with high energy phosphate loss [14,
15, 22, 32-35]. Administration of ribose increased the
synthesis of adenine nucleotides and prevented the drop
of cardiac function caused by isoproterenol infusion [14,
15]. It has, furthermore, been demonstrated that
continuous i.v. administration of ribose in rats with MI
attenuated the fall of the ATP levels in the non-ischemic
myocardium and accelerated their replenishment [20].
This was accompanied by a reduction of LVEDP after 2
and 4 d of ribose administration. Further cardioprotective
effects of a bolus ribose pretreatment have also been
described in global ischemia [23]. Also in clinical trials in
ischemic heart disease, ribose administration displayed
favorable effects by improving diastolic function and
quality of life and, of note, tolerance to ischemia [17, 18,
36].
In the current study, it is hard to differentiate
between the effects on the ischemic and the non-ischemic
myocardium, since heart function was measured globally,
the mRNA expression levels were measured in the
macroscopic ischemic area, whereas ATP levels were
not measured. However, it has been shown that ribose
increased adenine nucleotide levels in the previously
ischemic heart after reperfusion over a period of 72 h
[22] and in the non-infarcted heart even over 4 d [20].
It may thus be inferred that in the present experimental
situation, pre-ischemic ribose infusion for 24 h may have
brought the later ischemic myocardium into a more
favorable metabolic condition, i.e. increase in adenine
nucleotide content so that it could sustain ischemia better.
On the other hand, continuing ribose infusion for 6 h after
coronary artery ligation may have enabled the non-
ischemic part of the heart to dampen the wave-like
expansion of the ischemic area. The improved function
recorded at that time (Figs. 1 and 2) does actually confirm
this notion.
It has, however, also to be considered that both, the
necrotic wave front and its detectability develop
dynamically, but little data are available in rats. In dogs,
which develop collaterals, it appears to take up to 6 h
until the wave front of cell death beginning at 15 to 20
minutes after the onset of ischemia from the
subendocardial region reaches the less ischemic
subepicardial region and the final transmural extent of
the infarct is established [37]. This, on the other hand,
also depends on time, rate of oxygen consumption,
collateral flow, mode of ischemia, and on the species
investigated [38]. Furthermore, the lack of reperfusion
prolongs the time after which TTC staining would
allow a clear differentiation between living and necrotic
areas. Recent studies indicate that an observation period
as short as 2 h is sufficient for a reliable detection of the
infarct area in a model of ischemia/ reperfusion in mice
[39]. Therefore, 6 h may be sufficient in a rat model of
permanent coronary artery occlusion. It should,
finally, also be mentioned that positive TTC staining does
not verify that these myocytes would function normally,
since positive TTC staining may also occur in stunning or
hibernating myocardium. Therefore, the attenuation of
LV dysfunction after MI by pretreatment with ribose may
be attributed to both, its effects on non-infarct zone as
well as on the infarct area. The current study indicates
that ribose has cardioprotective effects on the ischemic
myocytes. Further studies will be needed to investigate if
ribose may be beneficial in a more clinically relevant
setting to treat acute myocardial infarction and
reperfusion injury.
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